Showing 2861-2870 of 5973 results for "".
- Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ as Lowest Priced Injectable Biologic For Psoriasishttps://practicaldermatology.com/news/valeants-patient-access-and-pricing-committee-announces-pricing-for-siliq-as-lowest-priced-injectable-biologic-for-psoriasis/2458215/Following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), Valeant Pharmaceuticals International, Inc. has decided to list SILIQ (brodalumab) injection at $3,500 per month, which is the lowest injectable biologic psoriasis treatment cur
- Topical Cannabinoids May Soothe Itchy Skinhttps://practicaldermatology.com/news/topical-cannabinoids-may-soothe-itchy-skin/2458218/Cannabinoids contain anti-inflammatory properties that may make them useful in the treatment of a wide-range of skin diseases including eczema, psoriasis, atopic and contact dermatitis, according to researchers at the University of Colorado Anschutz Medical Campus. The new study app
- New “Sonoillumination” Waveguide Device Set to Improve Laser Surgeryhttps://practicaldermatology.com/news/new-sonoillumination-waveguide-device-set-to-improve-laser-surgery/2458221/One of the biggest issues with the lasers used to treat benign vascular birthmarks, port-wine stains and for tattoo removal is making sure the laser light, which is held at a distance from the skin, is perfectly and selectively absorbed by only the targeted birthmark or tattoo. Paul J.D.
- Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategyhttps://practicaldermatology.com/news/allergan-names-daphne-karydas-as-senior-vice-president-of-global-investor-relations-strategy/2458224/Daphne Karydas is Allergan’s new Senior Vice President of Global Investor Relations and Strategy, effective April 17, 2017. In this role, Ms. Karydas will lead the Company's engagement with the investment community, and will work with
- FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to Humira Prescribing Informationhttps://practicaldermatology.com/news/fda-approves-addition-of-moderate-to-severe-fingernail-psoriasis-data-to-humira-prescribing-information/2458232/The FDA approved the inclusion of moderate to severe fingernail psoriasis data in AbbVie's Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis. Humira is the first biologic treatment with data on fingernail psoriasis in its US prescribing
- No Antibiotics Needed For Mild Infected Eczema in Kidshttps://practicaldermatology.com/news/no-antibiotics-needed-for-mild-infected-eczema-in-kids/2458238/Oral or topical antibiotics are not effective for treating milder clinically infected eczema in children, a new study shows. In the study of 113 children with clinical, non-severely infected eczema, participants received either oral
- 5α-Reductase Inhibitors Not Associated with Increased Suicide Risk in Older Menhttps://practicaldermatology.com/news/5-reductase-inhibitors-not-associated-with-increased-suicide-risk-in-older-men/2458240/Using 5α- reductase inhibitors was not associated with increased suicide risk in a group of older men, according to new research in JAMA Internal Medicine. Risks f
- Pershing Square Capital Management, L.P. Announces Sale of Its Investment In Valeant Pharmaceuticals International, Inc.https://practicaldermatology.com/news/pershing-square-capital-management-lp-announces-sale-of-its-investment-in-valeant-pharmaceuticals-international-inc/2458249/Pershing Square Capital Management, L.P. (“Pershing Square”) announced today that it has sold its investment in Valeant Pharmaceuticals International, Inc. (“Valeant”) (ticker: NYSE: VRX). Pershing Square CEO Bill Ackman and Vice Chairman Steve Fraidin will remain on the V
- Serlopitant May Stop the Itch of Prurigo Nodularishttps://practicaldermatology.com/news/serlopitant-may-stop-the-itch-of-prurigo-nodularis/2458252/Menlo Therapeutics Inc.’s Serlopitant performed well in phase 2 trial (TCP-102) evaluating it as a treatment of pruritus associated with prurigo nodularis, successfully meeting its primary efficacy endpoint and key sec
- Modernizing Medicine and Galderma Team Up to Offer Integrated OTC eCommerce Platformhttps://practicaldermatology.com/news/modernizing-medicine-and-galderma-team-up-to-offer-integrated-otc-ecommerce-platform/2458264/Specialty-specific health information technology company Modernizing Medicine, Inc. and Galderma Laboratories, L.P. are collaborating to deliver new capabilities in support of improved patient experiences and outcomes through healthcare provider recommended over-